Skip to main content

Table 1 Cohort characteristics. P value for difference between proportion of clinical characteristic within TAP positive and negative patients determined with a two-proportion z-test, except for age and tumor size for which a t-test was employed

From: Expression of a-Tocopherol-Associated protein (TAP) is associated with clinical outcome in breast cancer patients

 

All cases

TAP negative

TAP positive

 
 

No. of patients

%

No. of patients

%

No. of patients

%

P value

Total

271

 

183

 

88

  

Grade

 1

34

12.5

20

10.9

14

15.9

0.33

 2

105

38.7

59

32.2

46

52.3

0.02

 3

92

33.9

78

42.6

14

15.9

0.03

 Unknown

40

14.8

26

14.2

14

15.9

nd

Stage

 I

97

35.8

60

32.8

37

42

0.18

 II

137

50.6

94

51.4

43

48.9

0.39

 III

31

11.4

23

12.6

8

9.1

0.4

 Unknown

6

2.2

6

3.3

 

0

nd

Age (avg, range)

 

58.1 (26–89)

56.9 (26–87)

62.6 (35–89)

<0.001

T

       

 T1

138

50.9

82

44.8

56

63.6

0.01

 T2

101

37.3

74

40.4

27

30.7

0.19

 T3

14

5.2

12

6.6

2

2.3

0.41

 T4

8

3

6

3.3

2

2.3

0.47

 Unknown

10

3.7

9

4.9

1

1.1

nd

N

 N0

150

55.4

97

53

53

60.2

0.2

 N1

108

39.9

74

40.4

34

38.6

0.43

 N2

6

2.2

5

2.7

1

1.1

0.46

 Unknown

7

2.6

7

3.8

 

0

nd

M

 M0

258

99.2

172

98.9

86

100

1

 M1

2

0.8

2

1.1

 

0

nd

 Unknown

11

 

9

 

2

 

nd

Tumor size (avg, cm)

 

2.09

 

2.39

 

1.83

 

<0.001

Received chemotherapy

       

 no

133

49.1

75

41

58

65.9

1

 yes

130

48

101

55.2

29

33

1

 Unknown

8

3

7

3.8

1

1.1

nd

ER

 ER-

65

24

58

31.7

7

8

0.1

 ER+

197

72.7

120

65.6

77

87.5

0

 Unknown

9

3.3

5

2.7

4

4.5

nd

HER2

 HER2-

116

42.8

85

46.4

31

35.2

1

 HER2+

72

26.6

43

23.5

29

33

1

 Unknown

83

30.6

55

30.1

28

31.8

nd

Hormone therapy

 No

77

26.7

57

28.8

20

22.2

0.28

 yes

187

64.9

120

60.6

67

74.4

0.03

 Unknown

24

8.3

21

10.6

3

3.3

nd

Back to article page